The Medical Letter on Drugs and Therapeutics
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Ambrisentan (Letairis – Gilead), a selective endothelin type A (ETA) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial hypertension (PAH).

THERAPY FOR PAH — New guidelines for treatment of PAH have recently been published.1 Standard management includes warfarin (Coumadin, and others), furosemide (Lasix, and others) and, in a small number of patients (after testing for vasoreactivity), a calcium channel blocker.2 For patients who need additional treatment, a systemic prostacyclin such as epoprostenol (Flolan) or treprostinil (Remodulin), both given as continuous infusions, or iloprost (Ventavis), given by multiple daily inhalations, is used. Oral options for PAH include sildenafil (Revatio), which inhibits phosphodiesterase ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
Article code: 1272b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian